Chemours Form 4: 1,294 Shares Withheld; Beneficial Ownership Corrected

Rhea-AI Filing Summary

Gerardo Familiar Calderon, an officer at The Chemours Company (CC), reported a transaction dated 09/01/2025 in which 1,294 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the withholding was executed at a price of $15.40 per share and no shares were sold. The filing shows 33,949.9429 shares beneficially owned following the transaction; that total was reduced to correct an inadvertent over-reporting in a prior Form 4 filed August 5, 2025. The Form 4 was executed on 09/03/2025 by an attorney-in-fact.

Positive

• Administrative withholding only: 1,294 shares were withheld solely to satisfy tax obligations, and no shares were sold in the open market.
• Correction to prior reporting: Beneficial ownership was reduced to correct an inadvertent over-reporting on the Form 4 filed August 5, 2025, improving disclosure accuracy.
• Exempt transaction: Transactions are noted as exempt from Section 16(b) pursuant to Rule 16b-3.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine tax-withholding on vested equity; not a market-sale signal and has limited impact on share count.

The transaction is a standard administrative withholding of 1,294 shares to meet tax obligations from vested restricted stock units and dividend equivalent units, executed at $15.40 per share. Such withholdings are exempt under Rule 16b-3 and do not represent open-market dispositions, so they typically carry minimal interpretive weight for company valuation or insider sentiment. The filing also corrects a prior over-reporting, which improves reporting accuracy but does not indicate a change in economic exposure beyond the withholding.

Corporate Governance Expert

TL;DR: Compliance-appropriate disclosure; correction enhances transparency but reflects no governance concern.

The Form 4 discloses a tax-withholding event and an explicit correction to previously reported beneficial ownership, demonstrating adherence to reporting obligations. The use of an attorney-in-fact signature is documented. There is no evidence in the filing of discretionary sales, option exercises beyond RSU vesting, or changes in control. From a governance perspective, the filing is routine and reflects corrective compliance rather than material governance risk.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Familiar Calderon Gerardo

(Last) (First) (Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres Advanced Performance Mat

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2025		F(1)		1,294	D	$15.4	33,949.9429(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Transactions are exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold.

2. Includes directly owned shares, restricted stock units and dividend equivalent units. The total number of shares reflected in Column 5 of Table I has been reduced to correct an inadvertent over-reporting of securities beneficially owned by the Reporting Person as previously reported in the Form 4 filed on August 5, 2025.

	/s/ Eric Stein, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for Chemours (CC) report on 09/01/2025?

The Form 4 reports that 1,294 common shares were withheld to satisfy tax obligations on vested restricted stock units and dividend equivalent units, at a price of $15.40 per share.

Did the reporting person sell any Chemours (CC) shares in this filing?

No; the filing states no shares were sold. The shares were withheld solely for tax withholding purposes.

How many shares does Gerardo Familiar Calderon beneficially own after the reported transaction?

The filing shows beneficial ownership of 33,949.9429 shares following the transaction; this number was reduced to correct a prior over-reporting.

Why were the transactions exempt from Section 16(b)?

The filing states the transactions are exempt pursuant to Rule 16b-3, which typically covers transactions related to compensatory equity awards such as RSU vesting.

Who signed the Form 4 and when was it executed?

The Form 4 was signed by Eric Stein, Attorney-in-Fact on 09/03/2025.